Novo Nordisk has entered a partnership with Vivtex to develop next generation oral biologic medicines for obesity and diabetes. The company has approved a €432 million investment to expand its oral ...

Novo Nordisk is expanding its tabletting facility in Monksland, Athlone, Ireland with a 432 million euro ($372.5 million) ...

Both Novo and obesity market rival Eli Lilly have outlaid significant funds to ensure future demand for oral weight loss drugs is met.

Pharmaceutical company Novo Nordisk has announced a €430m expansion of its manufacturing operation in Athlone which will see it produce the tablet form of its weight loss drug Wegovy.

Novo Nordisk has said it will invest DKK 3.2 billion (€432 million) in a manufacturing plant in Ireland that will be used to ...